HK1131147A1 - Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro- phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith - Google Patents

Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro- phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith

Info

Publication number
HK1131147A1
HK1131147A1 HK09110990.0A HK09110990A HK1131147A1 HK 1131147 A1 HK1131147 A1 HK 1131147A1 HK 09110990 A HK09110990 A HK 09110990A HK 1131147 A1 HK1131147 A1 HK 1131147A1
Authority
HK
Hong Kong
Prior art keywords
cyclohexan
purin
ylamino
phenylamino
trifluoro
Prior art date
Application number
HK09110990.0A
Other languages
English (en)
Inventor
Marie G Beauchamps
Robert Hilgraf
Mohit Atul Kothare
Louise Michelle Cameron
Manohar T Saindane
Jean Xu
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of HK1131147A1 publication Critical patent/HK1131147A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK09110990.0A 2006-10-27 2009-11-25 Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro- phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith HK1131147A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85475706P 2006-10-27 2006-10-27
PCT/US2007/022648 WO2008057252A2 (fr) 2006-10-27 2007-10-26 Formes solides comprenant un composé de 4-[9-(tétrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phénylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions contenant celles-ci et utilisation de celles-ci

Publications (1)

Publication Number Publication Date
HK1131147A1 true HK1131147A1 (en) 2010-01-15

Family

ID=39149400

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09110990.0A HK1131147A1 (en) 2006-10-27 2009-11-25 Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro- phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
HK12107742.2A HK1166983A1 (zh) 2006-10-27 2012-08-07 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12107742.2A HK1166983A1 (zh) 2006-10-27 2012-08-07 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途

Country Status (17)

Country Link
US (2) US8158635B2 (fr)
EP (2) EP2076516B1 (fr)
JP (2) JP5523833B2 (fr)
KR (2) KR20090084891A (fr)
CN (2) CN101568544B (fr)
AU (1) AU2007318132B2 (fr)
BR (1) BRPI0717394A2 (fr)
CA (1) CA2667345C (fr)
ES (2) ES2442257T3 (fr)
HK (2) HK1131147A1 (fr)
IL (1) IL198227A (fr)
MX (1) MX2009003913A (fr)
NO (1) NO20092021L (fr)
NZ (3) NZ598071A (fr)
RU (2) RU2496780C2 (fr)
WO (1) WO2008057252A2 (fr)
ZA (1) ZA201007905B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP2076516B1 (fr) * 2006-10-27 2013-12-11 Signal Pharmaceuticals LLC Formes solides comprenant un composé de 4-[9-(tétrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phénylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions contenant celles-ci et utilisation de celles-ci
US20130034495A1 (en) * 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US9617517B2 (en) 2011-05-02 2017-04-11 National University Corporation Kumamoto University Small chemical compound which promotes induction of differentiation of stem cells into insulin-producing cells and method for inducing differentiation of stem cells into insulin-producing cells using said small chemical compound
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
CN103396371B (zh) * 2013-08-26 2015-12-02 南京优科生物医药研究有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2015071602A1 (fr) * 2013-11-15 2015-05-21 Universite Claude Bernard Lyon I Solution aqueuse de conservation d'un organe et utilisations lors de l'ischemie hypothermique
KR20230035424A (ko) 2014-10-06 2023-03-13 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
DK3436019T3 (da) * 2016-04-01 2021-10-11 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorphenyl)amino)-9h-purin-9-yl)-1-methylcyclohexan-1-carboxamid og fremgangsmåder til anvendelse deraf
EP3436018A4 (fr) 2016-04-01 2019-11-13 Signal Pharmaceuticals, LLC Composés aminopurine substitués, compositions correspondantes, et procédés de traitement les utilisant
CN109563095B (zh) 2016-06-02 2021-10-29 细胞基因公司 动物和人抗疟剂
CN109476696B (zh) 2016-06-02 2022-06-10 细胞基因公司 动物及人抗锥虫和抗利什曼原虫剂
CN107759600A (zh) * 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
KR20200061363A (ko) 2017-10-04 2020-06-02 셀진 코포레이션 시스-4-[2-｛[(3ｓ,4ｒ)-3-플루오로옥산-4-일]아미노｝-8-(2,4,6-트리클로로아닐리노)-9ｈ-퓨린-9-일]-1-메틸사이클로헥산-1-카르복스아미드의 제조 공정
AU2018345647A1 (en) 2017-10-04 2020-04-16 Celgene Corporation Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide
CA3138240A1 (fr) * 2019-04-30 2020-11-05 Shijiazhuang Sagacity New Drug Development Co., Ltd. Formes cristallines d'un compose inhibiteur de wee1 et utilisation connexe
CN115326970B (zh) * 2022-08-17 2024-03-29 上海卓鼎生物技术有限公司 一种7-Troc-巴卡亭Ⅲ-13-O-恶唑啉羧酸酯的检测方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758222A (fr) * 1969-10-29 1971-04-01 Norsk Hydro As Procede de preparation de chlorure de magnesium convenant pour la production du magnesium par electrolyse du sel fondu
US4155881A (en) * 1978-03-08 1979-05-22 E. I. Du Pont De Nemours And Company Activation of chromic fluoride catalyst with hydrogen chloride and chlorine
US4472531A (en) * 1980-01-14 1984-09-18 National Petro Chemicals Corporation Polymerization catalyst and method of preparing the same
US4386202A (en) * 1981-06-05 1983-05-31 Monsanto Company Chloroammelides and their preparation
JPS60231683A (ja) * 1984-05-02 1985-11-18 Teijin Ltd セフアロスポリン誘導体その製造法及びそれを有効成分とする抗菌剤
DE19516609C2 (de) * 1995-05-10 1997-08-14 Degussa Verfahren zur Herstellung von abriebfestem Natriumperborat-monohydrat mit hoher Schüttdichte und hoher Lösegeschwindigkeit
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US5753635A (en) * 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
SK2482001A3 (en) * 1998-08-27 2002-01-07 Teva Pharma Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
US6468976B1 (en) * 2001-09-10 2002-10-22 Astrazeneca Ab Monohydrate lisinopril
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US20040194664A1 (en) * 2002-08-05 2004-10-07 Elementis Pigments, Inc. Low sulfur red iron oxide useful as a catalyst or catalyst component and a process for making low sulfur red iron oxide
EP1660495B1 (fr) * 2003-09-04 2007-07-11 Wockhardt Limited Arginine tetrahydrate d'acide benzoquinolizine-2-carboxylique
US7256196B1 (en) 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US20060287289A1 (en) * 2004-03-16 2006-12-21 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
WO2007027525A1 (fr) * 2005-08-29 2007-03-08 Sanofi-Aventis U.S. Llc Nouvelle forme cristalline d'un derive de pyridazino [4,5-b]indole
WO2007032808A1 (fr) * 2005-09-12 2007-03-22 Dr. Reddy's Laboratories Ltd. Trihydrate cristallin de l'acide zolédronique
WO2007073424A1 (fr) * 2005-09-13 2007-06-28 Sicor, Inc. Bromure de rocuronium pur
MX2009003405A (es) * 2006-09-28 2009-04-09 Merck & Co Inc Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
EP2076516B1 (fr) * 2006-10-27 2013-12-11 Signal Pharmaceuticals LLC Formes solides comprenant un composé de 4-[9-(tétrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phénylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions contenant celles-ci et utilisation de celles-ci
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2008143015A1 (fr) * 2007-05-18 2008-11-27 Ajinomoto Co., Inc. Procédé de production d'acide succinique et procédé de production d'une solution de succinate d'ammonium
EP2160394A1 (fr) * 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Co-cristaux de tenofovir disoproxil acide hémi-fumarique
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
EP2416670A4 (fr) * 2009-04-09 2014-05-21 Cargill Inc Composition d'édulcorant comprenant une forme de rébaudioside a à solubilité élevée et procédé de fabrication
WO2010138583A1 (fr) * 2009-05-29 2010-12-02 Cargill, Incorporated Procédé de fabrication de produits de type sel naturellement purifiés

Also Published As

Publication number Publication date
KR20090084891A (ko) 2009-08-05
CN102382113B (zh) 2016-04-06
ES2567051T3 (es) 2016-04-19
IL198227A0 (en) 2009-12-24
CA2667345A1 (fr) 2008-05-15
US20090048275A1 (en) 2009-02-19
NO20092021L (no) 2009-07-27
CN101568544B (zh) 2016-10-26
NZ576347A (en) 2011-10-28
JP2014058550A (ja) 2014-04-03
RU2009120026A (ru) 2010-12-10
EP2615091A3 (fr) 2014-01-22
EP2615091B1 (fr) 2016-01-20
HK1166983A1 (zh) 2012-11-16
RU2496780C2 (ru) 2013-10-27
KR20150028857A (ko) 2015-03-16
US8158635B2 (en) 2012-04-17
EP2076516B1 (fr) 2013-12-11
IL198227A (en) 2015-07-30
JP2010507673A (ja) 2010-03-11
CN101568544A (zh) 2009-10-28
CN102382113A (zh) 2012-03-21
MX2009003913A (es) 2009-04-24
EP2076516A2 (fr) 2009-07-08
AU2007318132A1 (en) 2008-05-15
RU2013134978A (ru) 2015-01-27
ES2442257T3 (es) 2014-02-10
ZA201007905B (en) 2012-06-29
BRPI0717394A2 (pt) 2013-10-15
WO2008057252A3 (fr) 2008-10-09
NZ589053A (en) 2012-03-30
EP2615091A2 (fr) 2013-07-17
WO2008057252A2 (fr) 2008-05-15
US20120115890A1 (en) 2012-05-10
AU2007318132B2 (en) 2012-11-08
NZ598071A (en) 2013-08-30
CA2667345C (fr) 2016-03-22
JP5523833B2 (ja) 2014-06-18

Similar Documents

Publication Publication Date Title
ZA201007905B (en) Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol,compositions thereof,and use therewith
TWI350756B (en) 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP2029588A4 (fr) Tétrahydropyrido[3,4-d]pyrimidines et analogues associés
IL194010A (en) Pyrzolido [4,3– d] derivatives, pyrimidine containing preparations and their use
AP2710A (en) Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
TWI319320B (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
HK1103730A1 (en) Pyrrolopyridine derivatives and their use as crth2antagonists
IL202622A (en) Purin derivatives and pharmaceuticals containing them
ZA201004565B (en) 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
PL2526930T3 (pl) Formulacja witaminowa
IL204763A0 (en) 6,7 - or 8 - substituted quinazolinone derivatives and compositions comprising and methods of using the same
SI1912990T1 (sl) Hidrokloridi in hidrati 1-((3-ciano-piridin-2-il)metil))-3-metil-7-(2-butin-1-il)8-(3-amino-pi- peridin-1-il)-ksantina, njihova priprava in njihova uporaba kot zdravila
IL204776A (en) 8 - (1,3-Dihydro-Isoindole-2-Ill-Methyl) -2,9-Dihydro-1,2,7,9-Tetraazh-Phenalen-3-O and Pharmaceutical Preparations Containing It
EP1941901A4 (fr) Formulation à application externe et ses procédés de préparation et utilisations
EP2012791A4 (fr) 7,9-dihydro-purin-8-one et analogues associés utilisés en tant qu'inhibiteurs de hsp90
EP1940454A4 (fr) Preparation orale pour troubles enteriques et/ou rehydratation
IL186939A0 (en) Pyrimidine derivatives and their use as
ZA200804688B (en) Purine derivatives and methods of use thereof
IL179009A0 (en) Purine derivative
GB2453011B (en) Antifolate agent compositions in the treatment of cancer
EP1951681A4 (fr) Nouveaux derives de 2-aminopyrimidine derivatives et leur utilisation
PT1858481T (pt) Composições oftalmológicas e sua utilização
EP1845099A4 (fr) Dérivés d'artémisine (qinghaosu), méthodes de synthèse et applications, et préparations pharmaceutiques contenant lesdits dérivés
IL199168A0 (en) Indolizine derivatives and the use thereof as antidiabetics
EP2029132A4 (fr) Compositions antihistaminiques et leur utilisation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181024